Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 366 (Pt 2), 595-601

Inhibitor Specificity of Recombinant and Endogenous caspase-9

Affiliations

Inhibitor Specificity of Recombinant and Endogenous caspase-9

Ciara A Ryan et al. Biochem J.

Abstract

Apoptosis triggered through the intrinsic pathway by radiation and anti-neoplastic drugs is initiated by the activation of caspase-9. To elucidate control mechanisms in this pathway we used a range of synthetic and natural reagents. The inhibitory potency of acetyl-Asp-Glu-Val-Asp-aldehyde ('Ac-DEVD-CHO'), benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone ('Z-VAD-FMK') and the endogenous caspase inhibitor X-chromosome-linked inhibitor of apoptosis protein ('XIAP') against recombinant caspase-9 were predictive of the efficacy of these compounds in a cell-free system. However, the viral proteins CrmA and p35, although potent inhibitors of recombinant caspase-9, had almost no ability to block caspase-9 in this system. These findings were also mirrored in cell expression studies. We hypothesize that the viral inhibitors CrmA and p35 are excluded from reacting productively with the natural form of active caspase-9 in vivo, making the potency of inhibitors highly context-dependent. This is supported by survival data from a mouse model of apoptosis driven by Sindbis virus expressing either p35 or a catalytic mutant of caspase-9. These results consolidate previous findings that CrmA is a potent inhibitor of caspase-9 in vitro, yet fails to block caspase-9-mediated cell death.

Similar articles

See all similar articles

Cited by 17 articles

See all "Cited by" articles

References

    1. Cell Death Differ. 1999 Nov;6(11):1028-42 - PubMed
    1. J Biol Chem. 1998 Apr 3;273(14):7787-90 - PubMed
    1. Cell Death Differ. 1999 Nov;6(11):1081-6 - PubMed
    1. Genes Dev. 1999 Dec 15;13(24):3179-84 - PubMed
    1. Structure. 2000 Jul 15;8(7):789-97 - PubMed

Publication types

Feedback